Becton, Dickinson and Company – NYSE:BDXB
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Becton, Dickinson and Company stock price monthly change
-3.81%
month
Becton, Dickinson and Company stock price quarterly change
+0.17%
quarter
Becton, Dickinson and Company stock price yearly change
-4.98%
year
Becton, Dickinson and Company key metrics
Market Cap | 13.69B |
Enterprise value | 84.65B |
P/E | 38.33 |
EV/Sales | 4.19 |
EV/EBITDA | 19.87 |
Price/Sales | 3.28 |
Price/Book | 1.15 |
PEG ratio | 1.12 |
EPS | 5.13 |
Revenue | 19.83B |
EBITDA | 4.92B |
Income | 1.51B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 8.55% |
Oper. margin | 13.08% |
Gross margin | 45.22% |
EBIT margin | 13.08% |
EBITDA margin | 24.86% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBecton, Dickinson and Company stock price history
Becton, Dickinson and Company stock forecast
Becton, Dickinson and Company financial statements
| Mar 2023 | 4.82B | 460M | 9.54% |
|---|---|---|---|
| Jun 2023 | 4.87B | 407M | 8.34% |
| Sep 2023 | 5.08B | 108M | 2.12% |
| Mar 2024 | 5.04B | 537M | 10.64% |
| 2019-11-05 | 3.3 | 3.31 |
|---|---|---|
| 2020-02-06 | 2.63 | 2.65 |
| 2020-05-07 | 2.32 | 2.55 |
| 2020-08-06 | 2.04 | 2.2 |
1.70%
Yield TTM
| Payout ratio | 63.73% |
|---|
| 2020 | 1.62% |
|---|---|
| 2021 | 1.51% |
| 2022 | 1.7% |
| 2023 | 1.51% |
| 2024 | 1.57% |
| Mar 2023 | 54394000000 | 28.70B | 52.77% |
|---|---|---|---|
| Jun 2023 | 53017000000 | 27.08B | 51.08% |
| Sep 2023 | 52780000000 | 26.98B | 51.13% |
| Mar 2024 | 54157000000 | 28.50B | 52.64% |
| Mar 2023 | 184M | -233M | 1.36B |
|---|---|---|---|
| Jun 2023 | 1.08B | -329M | -1.79B |
| Sep 2023 | 1.32B | 137M | -998M |
| Mar 2024 | 515M | -1.05B | 1.70B |
Becton, Dickinson and Company alternative data
| Aug 2023 | 77,000 |
|---|---|
| Sep 2023 | 77,000 |
| Oct 2023 | 77,000 |
| Nov 2023 | 77,000 |
| Dec 2023 | 77,000 |
| Jan 2024 | 77,000 |
| Feb 2024 | 77,000 |
| Mar 2024 | 77,000 |
| Apr 2024 | 77,000 |
| May 2024 | 77,000 |
| Jun 2024 | 77,000 |
| Jul 2024 | 77,000 |
Becton, Dickinson and Company other data
5.12%
-4.86%
of BDXB is owned by hedge funds
65
-24
14.61M
-14.06M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 0 | 475 |
| Jun 2022 | 0 | 443 |
| Aug 2022 | 0 | 28107 |
| Feb 2023 | 0 | 1421 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BYRD RICHARD officer: EVP & President Interv.. | Common Stock | 1,421 | $248.6 | $353,261 | ||
Option | GOETTE ROLAND officer: EVP and President, EMEA | Stock Appreciation Rights | 4,617 | $74.94 | $345,998 | ||
Option | GOETTE ROLAND officer: EVP and President, EMEA | Common Stock | 4,617 | $74.94 | $345,998 | ||
Option | POLEN THOMAS E JR director, officer.. | Stock Appreciation Rights | 15,000 | $167.91 | $2,518,650 | ||
Option | POLEN THOMAS E JR director, officer.. | Stock Appreciation Rights | 15,000 | $167.91 | $2,518,650 | ||
Option | POLEN THOMAS E JR director, officer.. | Stock Appreciation Rights | 15,000 | $167.91 | $2,518,650 | ||
Sale | POLEN THOMAS E JR director, officer.. | Common Stock | 9,500 | $265.13 | $2,518,735 | ||
Sale | POLEN THOMAS E JR director, officer.. | Common Stock | 9,500 | $265.13 | $2,518,735 | ||
Sale | POLEN THOMAS E JR director, officer.. | Common Stock | 9,500 | $265.13 | $2,518,735 | ||
Option | POLEN THOMAS E JR director, officer.. | Common Stock | 15,000 | $167.91 | $2,518,650 |
| Patent |
|---|
Grant Filling date: 5 Aug 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 11 Jul 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 17 Nov 2017 Issue date: 20 Sep 2022 |
Grant Utility: Flow cytometers having enclosed droplet sorters with controlled aerosol content and methods of using the same Filling date: 23 Nov 2020 Issue date: 13 Sep 2022 |
Grant Design: Injection site tool Filling date: 26 Feb 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 14 Jan 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 15 Oct 2018 Issue date: 13 Sep 2022 |
Grant Filling date: 30 Apr 2019 Issue date: 6 Sep 2022 |
Grant Utility: Process tube and carrier tray Filling date: 29 Jan 2019 Issue date: 6 Sep 2022 |
Application Filling date: 20 May 2022 Issue date: 1 Sep 2022 |
| Insider | Compensation |
|---|---|
| Mr. Thomas E. Polen Jr. (1973) Pres, Chief Executive Officer & Chairman | $3,690,000 |
Mr. Alberto Mas (1961) Executive Vice President & Pres of the Medical Segment | $1,580,000 |
| Mr. Samrat S. Khichi Esq. (1967) Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel | $1,460,000 |
| Mr. Simon D. Campion (1971) Executive Vice President & Pres of Interventional Segment | $1,310,000 |
| Mr. Christopher DelOrefice (1971) Executive Vice President & Chief Financial Officer | $511,650 |
-
When is Becton, Dickinson and Company's next earnings date?
Unfortunately, Becton, Dickinson and Company's (BDXB) next earnings date is currently unknown.
-
Does Becton, Dickinson and Company pay dividends?
Yes, Becton, Dickinson and Company pays dividends and its trailing 12-month yield is 1.7% with 64% payout ratio. The last Becton, Dickinson and Company stock dividend of $0.75 was paid on 4 Sep 2025.
-
How much money does Becton, Dickinson and Company make?
Becton, Dickinson and Company has a market capitalization of 13.69B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.16% to 20.18B US dollars. Becton, Dickinson and Company earned 1.71B US dollars in net income (profit) last year or $2.2 on an earnings per share basis.
-
What is Becton, Dickinson and Company's stock symbol?
Becton, Dickinson and Company is traded on the NYSE under the ticker symbol "BDXB".
-
What is Becton, Dickinson and Company's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Becton, Dickinson and Company?
Shares of Becton, Dickinson and Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Becton, Dickinson and Company's key executives?
Becton, Dickinson and Company's management team includes the following people:
- Mr. Thomas E. Polen Jr. Pres, Chief Executive Officer & Chairman(age: 52, pay: $3,690,000)
- Mr. Alberto Mas Executive Vice President & Pres of the Medical Segment(age: 64, pay: $1,580,000)
- Mr. Samrat S. Khichi Esq. Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel(age: 58, pay: $1,460,000)
- Mr. Simon D. Campion Executive Vice President & Pres of Interventional Segment(age: 54, pay: $1,310,000)
- Mr. Christopher DelOrefice Executive Vice President & Chief Financial Officer(age: 54, pay: $511,650)
-
How many employees does Becton, Dickinson and Company have?
As Jul 2024, Becton, Dickinson and Company employs 77,000 workers.
-
When Becton, Dickinson and Company went public?
Becton, Dickinson and Company is publicly traded company for more then 5 years since IPO on 21 May 2020.
-
What is Becton, Dickinson and Company's official website?
The official website for Becton, Dickinson and Company is bd.com.
-
Where are Becton, Dickinson and Company's headquarters?
Becton, Dickinson and Company is headquartered at 1 Becton Drive, Franklin Lakes, NJ.
-
How can i contact Becton, Dickinson and Company?
Becton, Dickinson and Company's mailing address is 1 Becton Drive, Franklin Lakes, NJ and company can be reached via phone at +20 18476800.
Becton, Dickinson and Company company profile:
Becton, Dickinson and Company
bd.comExchange:
NYSE
Full time employees:
77,000
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
1 Becton Drive
Franklin Lakes, NJ 07417-1880
Franklin Lakes, NJ 07417-1880
CIK: 0000010795
ISIN: US0758874061
CUSIP: 075887406
